Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis

American Journal of Kidney Diseases

Volumn 32, Issue 3, 1998, Pages 488-493

  Wakeen, Maureen ^a   Zimmerman, Stephen W ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Amputations; Coagulability; EPO; Microvascular; Peripheral vascular

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AMPUTATION; ANEMIA; ARTICLE; DIABETES MELLITUS; DRUG EFFECT; ERYTHROPOIESIS; HUMAN; MAJOR CLINICAL STUDY; PERIPHERAL VASCULAR DISEASE; PERITONEAL DIALYSIS;

EID: 0031662866     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9740167     Document Type: Article

References (33)

1. Eschbach JW, Aquiling T, Haley NR: The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 38:S98-S103, 1992
2. Yamakado M, Umezu M, Nagano M, Tagawa H: Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis. Clin Invest Med 14:623-629, 1991
3. Windus D: The effect of comorbid conditions on hemodialysis access patency. Adv Renal Replacement Ther 1:148-154, 1994
4. Horina J, Fazekas F, Niederkorn K, Payer F, Valetitsch H, Winkler H, Horner S, Freidl W, Pogglitsch H, Krejs G: Cerebral hemodynamic changes following treatment with erythropoietin. Nephron 58:407-412, 1991
5. Canaud B, Polito C, Mathieu-Daude JC, Peterlongo F, Mion C: Erythropoietin-associated hypertension: What role for blood viscosity changes? Nephron 51:430-431, 1989
6. Creutzig A, Caspary L, Nonnast-Daniel B, Bahlmann J, Kuhn K, Brunkhorst R, Reimers E, Koch KM, Alexander K: Skin microcirculation and regional peripheral resistance in patients with chronic renal anaemia treated with recombinant human erythropoietin. Eur J Clin Invest 20:219-233, 1990
7. Stefenelli TH, Boszoha A, Kaliman J-F, Mayer G, Graf H: Digital vascular reactivity in patients on haemodialysis treated with human recombinant erythropoietin. Vasa 20:70-73, 1991
8. Appel R: Unexpected nonocclusive mesenteric infarction during continuous ambulatory peritoneal dialysis. Am J Nephrol 14:230-232, 1994
9. Wirtz JJJM, Leunissen KML, van Kuijk W, Cheriex EC, Slaaf DW, Reneman RS, van Hoof JP: Long-term effects of recombinant human erythropoietin on macro- and microcirculation in chronic hemodialysis patients. Blood Purif 11:237-247, 1993
10. Koppensteiner R, Stockenhuber F, Jahn C, Blacke P, Minor E, Ehringer H: Changes in determinants of blood rheology during treatment with haemodialysis and recombinant human erythropoietin. Br Med J 300:1626-1627, 1990
11. Macdougall IC, Davies ME, Halleh I, Cochlin DL, Hutton RD, Coles GA, Williams JD: Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 6:862-867, 1991
12. Wirtz JJM, van Esser JWJ, Hamulyak K, Leunissen KML, van Hooff JP: The effects of recombinant human erythropoietin on haemostasis and fibrinolysis in hemodialysis patients. Clin Nephrol 38:277-282, 1992
13. Tomura S, Nakamura Y, Tachibana K, Deguchi F, Ando R, Chida Y, Marumo F: Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic hemodialysis. Blood Purif 11:370-377, 1993
14. Carlini R, Obialo C, Rothstein M: Intravenous erythropoietin (rHu EPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. AJH 6:103-107, 1993
15. Carlini R, Dusso A, Obialo C, Alverez U, Rothstein M: Recombinant human erythropoietin (rHu EPO) increases endothelin-1 release by endothelial cells. Kidney Int 43:1010-1014, 1993
16. Kaupke CJ, Butler GC, Vaziri ND: Effects of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 3:1672-1679, 1993
17. Zirkman D, Zeigler Z, Fraley D, Bruns F, Adler S: Evaluation of platelet hyperfunction in hemodialysis patients receiving recombinant human erythropoietin. Am J Kidney Dis 21:31-37, 1993
18. Yates CJP, Berent A, Andrews V, Dormandy JA: Increase in leg blood flow by normovolaemic haemodilution in intermittent claudication. Lancet 2:166-168, 1979
19. Bailey MJ, Johnston CLW, Yates CJP, Somerville PG, Dormandy JA: Preoperative haemoglobin as a predictor of outcomes of diabetic amputations. Lancet 2:168-170, 1979
20. Editorial. Haemoglobin and the ischaemic foot. Lancet 2:184-185, 1979
21. Neff MJ: Hemodynamics of uremic anemia. Circulation 43:876-883, 1971
22. Feriani M, Kimmel P, Kurantsin-Mills J, Bosch J: Effects of renal replacement therapy on viscosity in end stage renal disease patients. Am J Kidney Dis 19:131-139, 1992
23. Bertoli M, Gasparotto M, Vertolli U, Ruffatti A, DiLandro D, Romagnoli GF: Does hypercoaguability exist in CAPD patients? Perit Dial Bull 237:239, 1984
24. Arends JP, Krediet RT, Boeschoten EW, van der Lelie J, Veenhof CH, von dem Borne AE: Improvement of bleeding time, platelet aggregation and platelet count during CAPD treatment. Proc EDTA 18:280-285, 1981
25. Takahashi K, Totsune K, Mouri T: Endothelin in chronic renal failure. Nephron 66:373-379, 1994
26. Mac Rury SM, Lennie SE, McColl P, Balendra R, MacCuish AC, Lowe GD: Increased red cell aggregation in diabetes mellitus: Association with cardiovascular risk factors. Diabetic Med 10:21-26, 1993
27. Tzamaloukas A, Zager P, Harford A, Nevarez M, Quintana B, Avasthi P, Gibel L: Vascular disease: The critical risk factor for mortality in older patients on CAPD. Adv Peritoneal Dial 6:56-61, 1990
28. Bender F, Piraino B: Polycythemia in diabetic patients on CAPD. Adv Peritoneal Dial 7:77-80, 1991
29. Raine AE: Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet 1:97-99, 1988
30. Kannel W, D'Agostino R: Update on fibrinogen as a major cardiovascular risk factor: The Framingham study. JACC 15:156A, 1990
31. Lowe G, Dawes J, Lennie SE, Fowkes FG, Donnan PT, Housley E: Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease: The Edinburgh artery study. Circulation 87:1915-1920, 1993
32. Johnson W, McCarthy J, Yanagihara T, Osmundson P, Ilstrup D, Jenson B, Bowie EJW: Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability. Kidney Int 38:919-924, 1990
33. Dancy E, Wakeen M, Zimmerman SW: Cardiac and peripheral vascular morbidity in diabetes: Comparison of hemodialysis and peritoneal dialysis. J Am Soc Nephrol 8:217, 1997 (abstr)